Hastarita Lawrenti, M.D.
Medical Manager PT Kalbe Farma Tbk
Routine medical activities (including PV) such as providing updates of scientific information about certain drugs, encouraging doctors to write articles for Cermin Dunia Kedokteran, evaluating new products, sharing therapy trends and future therapy with marketing, implementing continuous improvement, and visiting health care providers periodically.
Responsibility of Pharmacovigilance
Reporting adverse events in compliance with regulatory requirements and company SOPs, whenever necessary
- Process and evaluate adverse event and medical error report from health care providers and public
GP from Medical Faculty, Sriwijaya University Palembang, Indonesia. Graduated year 2008.
|2010||Advanced Course on Safety Assessment of Cosmetics (Jakarta, Indonesia)|
|2012||Post Graduate Course on Oncology (Jakarta, Indonesia)|
|2017||Peningkatan Kompetensi Farmakovigilans Bagi Industri Farmasi (Surabaya, Indonesia)|
|2017||Developing risk management capability: Maximising opportunities from global pharmacovigilance experience (Bangkok, Thailand)|
|2020||Workshop of pharmacovigilance module for pharmaceutical industries (Jakarta, Indonesia)|
|2022||Short Course Basic Oncology Modules Program A (Breast, Colorectal, and Prostate Cancer) and Program B (Lung, Cervix, and Thyroid Cancer) (Jakarta, Indonesia)|
|April 2012||Management in Haematology and Medical Oncology Patients. Denpasar|
|April 2012||Asian Oncology Summit. Singapore|
|September 2012||ESMO Congress. Vienna, Austria|
|February 2013||Role of Internist in Cancer Management 2. Jakarta|
|December 2013||The 3rd Biennial Meeting Asian Society of Gynecologic Oncology. Kyoto, Japan.|
|March 2015||Role of Internist in Cancer Management 3. Jakarta|
|August 2015||6th Annual Scientific Meeting on Intensive Care. Kuala Lumpur, Malaysia|
|March 2016||Role of Internist in Cancer Management 4. Jakarta|
|May 2016||Pharmacovigilance: Drug Quality and Risk Management Program. Jogjakarta, Indonesia|
|April 2017||Role of Internist in Cancer Management 5. Jakarta|
|April 2018||International Society of Oncology Pharmacy Practitioners. Shanghai|
|Agustus 2018||Role of Internist in Cancer Management 6. Jakarta|
|Juli 2019||Role of Internist in Cancer Management 7. Jakarta|
|April 2020||Panduan Menjaga Imunitas Bagi Penyintas Kanker di Masa Pandemi COVID-19. Jakarta.|
|September 2020||Menuju Zero Kelahiran Talasemia Mayor. Jakarta.|
|December 2020||Acute Leukemia: Clinical and Laboratory Approach. Jakarta.|
|Maret 2021||Immunotherapy Management of Squamous Cell Carcinoma Head and Neck Cancer.|
|Juli 2021||Towards A New Era of Immunotherapy with Pembrolizumab as Treatment for Advanced RCC and Urothelial Cancer.|
|Agustus 2021||Therapy Management Update on EGFR+ Non-Small Cell Lung Cancer.|
|February 2022||Choosing CDK4/6i for HR+ HER2- Advanced Breast Cancer, What is the Difference?|
As speaker in the symposium of Indonesian Pulmonologist, entitled: “Role of Gemcitabine in Lung Cancer Management”, held in Palembang.
As speaker in the symposium, entitled: “Practical Guidelines for Chemotherapy Side Effects”, held in Denpasar.
As speaker in the Workshop: Safe Handling of Cytotoxic Drugs, held in Bandung.
As speaker in the Workshop: Care for Cancer Patients with Chemotherapy, held in Denpasar.
As speaker in the Workshop: Kemoterapi Lini Pertama Untuk Kanker Payudara, held in Jakarta.
As speaker in the Training: Training Peningkatan Kompetensi Farmakovigilans Industri Farmasi, held in Bekasi.
As speaker in the Symposium and Workshop: The Arrival of Trastuzumab and Rituximab Biosimilars in Oncology: Efficacy and Safety in Treatment of Cancer, held in Jakarta.
As speaker in the Webinar: Menjaga Kesehatan Thaller di Era Pandemik COVID-19, held in Bandung.
As speaker in the Webinar: Well Balanced Nutrition Combined with Supplementation for Thalassemia Patients During COVID-19 Pandemic, held in Jakarta.
As speaker in the Webinar: Manfaat Kelasi Besi pada Pasien Thalassemia, held in Banjarmasin.
As speaker in the Webinar: Manajemen Thalassemia dan Terapi Kelasi Besi, held in Surabaya.
As speaker in the Webinar: Optimizing Diagnostic Approach in Early Breast Cancer and Current Treatment of HER2+ Breast Cancer, held in Surabaya.
As speaker in the Webinar: Biosimilar Targeted Agents in Non-Hodgkin Lymphoma: Focus on Rituximab, held in Denpasar.
As speaker in the Webinar: Kupas Tuntas Thalassemia, held in Aceh.
As speaker in the Webinar: Seputar Thalassemia pada Anak, held in Jakarta.
As speaker in the Webinar: Management of Febrile Neutropenia for Cancer Patient, held in Jakarta